ML-336
(Synonyms: (E)-2-((1,4-二甲基哌嗪-2-亚基)氨基)-5-硝基-N-苯基苯甲酰胺) 目录号 : GC11348An antiviral selective against VEEV
Cas No.:1613465-33-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
IC50: 32, 20, and 41 nM for TC-83, V3526, and Trinidad donkey strains, respectively.
ML-336 is an inhibitor for VEEV-induced cytopathic effect.
Alphaviruses like Venezuelan Equine Encephalitis Virus (VEEV) are positive-sense, enveloped, single stranded RNA viruses that are widely geographically distributed. VEEVs are found to be arthropod-borne viruses that are known to cause arthritis, encephalitis, rash, as well as death in humans.
In vitro: ML336 was identified as a first-in-class probe that inhibited a VEEV-induced cytopathic effect in three strains of the virus, which were V3526, TC-83, and Trinidad donkey, in the low nanomolar range without having cytotoxicity (> 50 μM, selectivity index > 1500). In addition, ML336 could reduce viral titer (more than 7.2 log) dramatically below a 1 μM drug concentration. Furthermore, ML336 showed a favorable in vitro PK profile that included moderate blood-brain barrier permeability. More importantly, ML336 seemed to be able to target the VEEV [1].
In vivo: Currently, there is no animal in vivo data reported.
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] Chung D et al. ML336: Development of Quinazolinone-Based Inhibitors Against Venezuelan Equine Encephalitis Virus (VEEV). Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD): National Center for Biotechnology Information (US); 2010-2012 Dec 17.
| Cas No. | 1613465-33-0 | SDF | |
| 别名 | (E)-2-((1,4-二甲基哌嗪-2-亚基)氨基)-5-硝基-N-苯基苯甲酰胺 | ||
| 化学名 | 2-[(E)-(1,4-dimethyl-2-piperazinylidene)amino]-5-nitro-N-phenyl-benzamide | ||
| Canonical SMILES | CN1CCN(C)C/C1=N\C2=C(C(NC3=CC=CC=C3)=O)C=C([N+]([O-])=O)C=C2 | ||
| 分子式 | C19H21N5O3 | 分子量 | 367.4 |
| 溶解度 | ≤0.2mg/ml in ethanol;10mg/ml in DMSO;20mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7218 mL | 13.6091 mL | 27.2183 mL |
| 5 mM | 0.5444 mL | 2.7218 mL | 5.4437 mL |
| 10 mM | 0.2722 mL | 1.3609 mL | 2.7218 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: ≥95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet